Institute of Nuclear Medicine, University College London Hospital NHS Foundation Trust, London NW1 2BU, United Kingdom.
J Nucl Med. 2014 Jan;55(1):88-94. doi: 10.2967/jnumed.113.123547. Epub 2013 Dec 12.
The aim of this study was to prospectively compare whole-body PET/MR imaging and PET/CT, qualitatively and quantitatively, in oncologic patients and assess the confidence and degree of inter- and intraobserver agreement in anatomic lesion localization.
Fifty patients referred for staging with known cancers underwent PET/CT with low-dose CT for attenuation correction immediately followed by PET/MR imaging with 2-point Dixon attenuation correction. PET/CT scans were obtained according to standard protocols (56 ± 20 min after injection of an average 367 MBq of (18)F-FDG, 150 MBq of (68)Ga-DOTATATE, or 333.8 MBq of (18)F-fluoro-ethyl-choline; 2.5 min/bed position). PET/MR was performed with 5 min/bed position. Three dual-accredited nuclear medicine physicians/radiologists identified the lesions and assigned each to an exact anatomic location. The image quality, alignment, and confidence in anatomic localization of lesions were scored on a scale of 1-3 for PET/CT and PET/MR imaging. Quantitative analysis was performed by comparing the standardized uptake values. Intraclass correlation coefficients and the Wilcoxon signed-rank test were used to assess intra- and interobserver agreement in image quality, alignment, and confidence in lesion localization for the 2 modalities.
Two hundred twenty-seven tracer-avid lesions were identified in 50 patients. Of these, 225 were correctly identified on PET/CT and 227 on PET/MR imaging by all 3 observers. The confidence in anatomic localization improved by 5.1% when using PET/MR imaging, compared with PET/CT. The mean percentage interobserver agreement was 96% for PET/CT and 99% for PET/MR imaging, and intraobserver agreement in lesion localization across the 2 modalities was 93%. There was 10% (5/50 patients) improvement in local staging with PET/MR imaging, compared with PET/CT.
In this first study, we show the effectiveness of whole-body PET/MR imaging in oncology. There is no statistically significant difference between PET/MR imaging and PET/CT in respect of confidence and degree of inter- and intraobserver agreement in anatomic lesion localization. The PET data on both modalities were similar; however, the observed superior soft-tissue resolution of MR imaging in head and neck, pelvis, and colorectal cancers and of CT in lung and mediastinal nodal disease points to future tailored use in these locations.
本研究旨在前瞻性比较全身 PET/MR 成像与 PET/CT,定性和定量评估肿瘤患者的解剖病变定位,并评估观察者间和观察者内的置信度和一致性程度。
50 例已知癌症患者进行分期,首先进行低剂量 CT 衰减校正的 PET/CT,随后进行 2 点 Dixon 衰减校正的 PET/MR 成像。PET/CT 扫描按照标准方案进行(注射平均 367MBq 的 [18]F-FDG、150MBq 的 [68]Ga-DOTATATE 或 333.8MBq 的 [18]F-氟乙基胆碱后 56±20min;5 床位置/分钟)。PET/MR 采用 5 床位置/分钟进行。三位双认证核医学医师/放射科医师识别病变,并将其分配到确切的解剖位置。对 PET/CT 和 PET/MR 成像的图像质量、配准和病变定位的置信度进行 1-3 分的评分。通过比较标准化摄取值进行定量分析。使用组内相关系数和 Wilcoxon 符号秩检验评估两种模态的图像质量、配准和病变定位的观察者间和观察者内一致性。
50 例患者共发现 227 个示踪剂摄取病灶。其中,所有 3 位观察者均正确识别出 225 个病灶在 PET/CT 上,227 个病灶在 PET/MR 成像上。与 PET/CT 相比,使用 PET/MR 成像时,解剖定位的置信度提高了 5.1%。PET/CT 的平均观察者间一致性为 96%,PET/MR 成像为 99%,两种模态的观察者内病变定位一致性为 93%。与 PET/CT 相比,PET/MR 成像在局部分期方面有 10%(50 例患者中有 5 例)的改善。
在这项首次研究中,我们展示了全身 PET/MR 成像在肿瘤学中的有效性。在解剖病变定位的置信度和观察者间和观察者内一致性方面,PET/MR 成像与 PET/CT 之间没有统计学上的显著差异。两种模态的 PET 数据相似;然而,MR 成像在头颈部、骨盆和结直肠肿瘤以及 CT 在肺部和纵隔淋巴结疾病中的观察到的软组织分辨率优势表明,未来在这些部位有针对性地使用。